TROPISETRON

New Drug Approvals

TROPISETRON

89565-68-4
105826-92-4 (HCl)

 ICF 205-930, Navoban™

Molecular Formula: C₁₇H₂₀N₂O₂   Molecular Weight: 284.3529

Novartis (Originator)

Tropisetron (INN) is a serotonin 5-HT₃ receptor antagonist used mainly as an antiemetic to treat nausea and vomiting following chemotherapy, although it has been used experimentally as an analgesic in cases of fibromyalgia.^[1] The drug is available in a 5 mg oral preparation or in 2 mg intravenous form. It is marketed by Novartis in Europe, Australia, New Zealand, Japan, South Korea and the Philippines as Navoban, but is not available in the U.S. It is also available from Novell Pharmaceutical Laboratories and marketed in several Asian countries as Setrovel

Tropisetron is a 5-hydroxytryptamine receptor 3 (5-HT3) antagonist that was launched in 1992 by Novartis for the oral and injection treatment of chemotherapy-induced emesis. The drug has also been approved for the prophylaxis and treatment…

View original post 2,558 more words